1. What This Condition Is
Multiple myeloma is a cancer of plasma cells — the white blood cells in bone marrow that produce antibodies. In multiple myeloma, malignant plasma cells multiply uncontrollably in the bone marrow, crowding out healthy blood cells and producing abnormal proteins that damage the kidneys, weaken bones, and suppress immune function. Symptoms include bone pain (particularly in the spine and chest), fractures from weakened bones, fatigue from anemia, frequent infections, and kidney problems. Multiple myeloma is typically not curable, but modern treatment has extended survival significantly for many patients.
Multiple myeloma qualifies for VA presumptive service connection through two separate regulatory pathways.
Agent Orange presumptive (38 CFR 3.309(e)): Multiple myeloma is one of the original 14 Agent Orange presumptive conditions. Veterans exposed to tactical herbicides during qualifying service — in Vietnam, the Korean Demilitarized Zone between April 1, 1968 and August 31, 1971, or other covered locations — do not need to prove a direct medical connection between their herbicide exposure and their diagnosis. The Blue Water Navy Vietnam Veterans Act of 2019 extended this presumptive to veterans who served on ships in the territorial seas off the coast of the Republic of Vietnam.
Gulf War and post-9/11 presumptive (38 CFR 3.320b, effective January 10, 2025): A new regulation effective January 10, 2025 establishes multiple myeloma — including monoclonal gammopathy of undetermined significance (MGUS) — as a presumptive condition for covered veterans who served on or after August 2, 1990 in the Southwest Asia theater of operations or Somalia, or in qualifying post-9/11 locations. The regulation also covers myelodysplastic syndromes and myelofibrosis. Veterans covered under 38 CFR 3.320b have a separate and independent presumptive pathway based on exposure to fine particulate matter and airborne hazards during qualifying service, without needing to establish Agent Orange exposure. Both pathways should be argued in the alternative where the veteran's service history supports them.
Multiple myeloma is often diagnosed late, after years of subclinical disease, and at a stage when the veteran has already sustained significant bone damage, kidney injury, or other complications. Veterans should file immediately on diagnosis regardless of how much time has passed since qualifying service.
2. VA Rating Criteria
Multiple myeloma is rated under 38 CFR § 4.117, Diagnostic Code 7715 (Lymphatic System, malignant neoplasms of), applied by analogy to plasma cell malignancies, or under DC 7703 (Leukemia), depending on how the rating authority classifies the condition. Confirm the applicable diagnostic code with an accredited VSO or representative.
Active disease or treatment: A 100% rating applies during any period of active multiple myeloma or any period of treatment — including chemotherapy, immunomodulatory therapy, proteasome inhibitors, corticosteroids, radiation, stem cell transplant, or any combination thereof.
Post-treatment or remission: After a stem cell transplant or completion of a defined treatment course, the 100% rating continues for a minimum of six months. Following that period, the VA schedules a rating examination to assess residual disability.
Residual ratings: Common residuals after multiple myeloma treatment include peripheral neuropathy from chemotherapy, kidney damage from myeloma protein deposition, anemia, bone fractures and their sequelae, and immunosuppression. Each residual is evaluated separately under the applicable diagnostic code:
- Peripheral neuropathy: rated under peripheral nerve codes based on severity of motor and sensory deficit.
- Renal damage: rated under kidney condition codes based on function and lab values.
- Anemia: rated based on severity of hematologic impairment.
- Bone lesions and fractures: rated under the appropriate musculoskeletal codes based on functional loss.
Veterans should not assume that a stable or responding myeloma means their benefits end. The residual rating process captures the ongoing burden of disease and treatment even when active malignancy is not detectable.
3. What to Expect at Your C&P Exam
For active disease, the examiner will confirm the current diagnosis, treatment status, and functional limitations. Be prepared to describe the burden of your current treatment regimen — infusion schedules, hospitalizations, side effects, and the effect on your daily function and activity tolerance.
For a residual rating exam following stem cell transplant or treatment completion, the examiner will assess your current hematologic status, kidney function, bone integrity, and any neuropathy. Bring current lab results including complete blood count, comprehensive metabolic panel, immunofixation, serum protein electrophoresis (SPEP), and bone density studies if available.
Describe all treatment-related effects: numbness or tingling from neuropathy, fatigue limiting your activity, infections requiring hospitalization, and any bone pain or fractures from lytic lesions. The examiner must document each residual separately.
4. Evidence You Need to Win
Diagnosis: Hematology or oncology records confirming the diagnosis, including bone marrow biopsy, SPEP, and imaging (skeletal survey, PET scan, or MRI) showing plasma cell involvement. The records must document the myeloma stage and treatment history.
Service Record Evidence (Presumptive Claims): Documentation of qualifying service in Vietnam, the Korean DMZ during the covered period, or other herbicide-exposure locations. For most Vietnam veterans, the DD-214 with in-country service dates is sufficient. For Blue Water Navy veterans, ship logs or service records confirming vessel assignment.
No Nexus Letter Required for Presumptive Claims: If the Agent Orange presumptive applies, a medical nexus to service is not required. File on diagnosis with qualifying service documented.
Nexus Letter (Non-Presumptive Direct Claims): Veterans with multiple myeloma potentially arising from radiation exposure during service or other service-connected pathway need a hematologist or oncologist's nexus opinion.
DBQ Form: The appropriate malignant neoplasm or hematologic conditions DBQ. Your treating hematologist or oncologist should complete this form with current diagnosis, treatment status, and residual functional findings.
Residual Evidence: Neuropathy evaluations, kidney function labs, bone density and imaging results, and any documentation of treatment complications requiring hospitalization or additional intervention.
Personal Statement: Describe the functional impact of the disease and treatment. Describe fatigue, activity limitations, neuropathy symptoms, bone pain, infection frequency, and the daily burden of managing an ongoing malignant condition.
Buddy Statements (VA Form 21-10210): Family members or caregivers who can describe your functional limitations and treatment burden provide lay corroboration of the severity and persistence of symptoms.
5. Secondary Conditions to Consider
Peripheral Neuropathy: Thalidomide, bortezomib, and other drugs commonly used to treat multiple myeloma cause peripheral neuropathy in a significant percentage of patients. Secondary neuropathy from treatment of service-connected myeloma is ratable under peripheral nerve codes.
Chronic Kidney Disease: Myeloma protein (Bence-Jones protein) deposits in the kidneys and causes progressive renal damage. Secondary CKD is ratable under the kidney diagnostic codes based on creatinine, BUN, and functional status.
Anemia: Bone marrow infiltration by myeloma cells causes severe anemia that often requires transfusions or ESA therapy. Secondary anemia is separately evaluable.
Bone Fractures and Sequelae: Lytic lesions weaken bones and cause vertebral compression fractures, rib fractures, and long bone fractures. The musculoskeletal residuals of pathologic fractures — limitation of motion, chronic pain, deformity — are separately ratable under the applicable codes.
Depression and Anxiety: Living with a progressive, generally incurable malignancy produces significant psychological burden. Secondary mental health conditions are ratable under 38 CFR 3.310.
Immune Compromise and Recurrent Infections: Immunosuppression from myeloma and its treatment results in frequent serious infections. If infectious complications produce lasting organ damage, those residuals may be separately ratable.
6. Common Mistakes That Kill Claims
Not filing because the diagnosis came decades after Vietnam service. Multiple myeloma has no latency restriction under the Agent Orange presumptive. A 2025 diagnosis is covered for a veteran who served in Vietnam in 1968. File immediately on diagnosis.
Assuming the disease must be "cured" before filing. Multiple myeloma is a chronic, generally incurable condition. The 100% rating during active disease applies throughout treatment. Do not wait for remission or treatment completion to file — file on diagnosis.
Missing residual claims after treatment. Veterans who achieve partial or complete response to treatment sometimes receive a reduced rating at the residual exam without realizing they have compensable neuropathy, kidney damage, or bone residuals. Document all residuals before the residual rating exam.
Not pursuing Blue Water Navy coverage. Offshore Vietnam veterans denied before 2019 may now reopen their claims under the Blue Water Navy Vietnam Veterans Act. File a Supplemental Claim if you were previously denied under the old rule.
Not connecting stem cell transplant complications. Stem cell transplantation for multiple myeloma carries significant complication risks including graft-versus-host disease, secondary infections, and organ toxicity. Residuals of transplant complications are ratable if they produce functional impairment.
7. FWD Assist Resources
The following FWD Assist HQ books are directly relevant to a multiple myeloma claim:
- Agent Orange: The Complete Vietnam Veterans Claims Guide — comprehensive coverage of the presumptive list including multiple myeloma, qualifying service locations, Blue Water Navy provisions, and how to file
- C&P Exam Prep Guide — covers what to expect at a cancer residual exam and how to document each residual condition for the rating evaluation
- Secondary Conditions Guide — walks through the neuropathy, kidney, and mental health secondary chains from service-connected cancer and cancer treatment
- The PACT Act Playbook — covers PACT Act expanded presumptives relevant to veterans whose service falls under the 2022 statutory expansion
All titles are available at fwdassisthq.com.
8. Get Help Without a Claim Shark
Free, accredited help is available through Veterans Service Organizations including the DAV, VFW, American Legion, and AMVETS. County Veterans Service Officers (CVSOs) file and manage claims at no cost.
Charging upfront fees to assist with a VA claim is illegal under 38 U.S.C. § 5905. VA-accredited attorneys and claims agents may charge fees only after an initial VA decision, capped at 20% of past-due benefits under 38 U.S.C. § 5904. No legitimate representative asks for money before your first decision.
Verify accreditation at va.gov/ogc/accreditation.asp.